argenx SE
Commercial immunology biotech led by VYVGART, with ongoing registrational expansion across myasthenia gravis, myositis and other autoimmune diseases plus a Phase 3 pipeline including empasiprubart.
Autoimmune & neuromuscular disease · FcRn-targeting antibody fragments & immunology biologics · Commercial + Phase 3